Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BT5528 phase I/II study in advanced EphA2-expressing solid tumors
2024-510655-36-00Phase 2Completed
- Sponsor
- Bicycle Therapeutics
- Start
- Feb 2022
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 5
01
Overview
Phase 2, open-label trial of nuzefatide pevedotin in Nonhematologic neoplasms and cancer (2 arms), sponsored by Bicycle Therapeutics. Primary endpoints: Safety and tolerability, Dose-limiting toxicities and 1 more. Started Feb 2022; status: completed.
02
Drugs
nuzefatide pevedotin
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on 2024-510655-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510655-36-00.